CeriBell (CBLL) Projected to Post Quarterly Earnings on Thursday

CeriBell (NASDAQ:CBLL - Get Free Report) is projected to post its Q1 2025 quarterly earnings results after the market closes on Thursday, May 8th. Analysts expect CeriBell to post earnings of ($0.43) per share and revenue of $19.30 million for the quarter. CeriBell has set its FY 2025 guidance at EPS.

CeriBell (NASDAQ:CBLL - Get Free Report) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.08). The company had revenue of $18.53 million for the quarter, compared to analysts' expectations of $17.55 million. On average, analysts expect CeriBell to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

CeriBell Stock Performance

Shares of CBLL stock traded down $0.41 during mid-day trading on Tuesday, hitting $15.78. 171,000 shares of the stock were exchanged, compared to its average volume of 270,146. CeriBell has a 12-month low of $10.01 and a 12-month high of $32.75. The firm's fifty day moving average price is $18.67.

Wall Street Analysts Forecast Growth

CBLL has been the subject of several research analyst reports. Canaccord Genuity Group reissued a "buy" rating and issued a $33.00 price objective on shares of CeriBell in a report on Wednesday, February 26th. LADENBURG THALM/SH SH assumed coverage on shares of CeriBell in a research report on Friday, April 4th. They set a "buy" rating and a $32.00 price objective on the stock. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average price target of $32.50.

Insider Transactions at CeriBell

In related news, CEO Xingjuan Chao sold 15,628 shares of the stock in a transaction dated Wednesday, April 23rd. The shares were sold at an average price of $15.11, for a total transaction of $236,139.08. Following the completion of the transaction, the chief executive officer now directly owns 727,151 shares of the company's stock, valued at $10,987,251.61. This represents a 2.10 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. In the last quarter, insiders sold 24,700 shares of company stock worth $372,434.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.